Laetitia Gerlier

Publication Activity (10 Years)

Years Active: 2021-2024
Publications (10 Years): 4

Top Topics

Combination Therapy

Ankylosing Spondylitis

Quality Improvement

Top Venues

Journal of medical economics

This page only lists publications with an associated author ORCID identifier.

Publications

Michael F Mørup, Vanessa Taieb, Damon Willems, Micah Rose, Nikos Lyris, Mark Lamotte, Laetitia Gerlier, Howard Thom
The cost-effectiveness of a bimekizumab versus IL-17A inhibitors treatment-pathway in patients with active axial spondyloarthritis in Scotland. Journal of medical economics (2024)
Michael F Mørup, Vanessa Taieb, Damon Willems, Micah Rose, Nikos Lyris, Mark Lamotte, Laetitia Gerlier, Howard Thom
The cost-effectiveness of a bimekizumab versus IL-17A inhibitors treatment-pathway in patients with active axial spondyloarthritis in Scotland. Journal of medical economics 27 (1) (2024)
Michael F Mørup, Vanessa Taieb, Damon Willems, Micah Rose, Nikos Lyris, Mark Lamotte, Laetitia Gerlier, Howard Thom
The cost-effectiveness of a bimekizumab versus IL-17A inhibitors treatment-pathway in patients with active axial spondyloarthritis in Scotland. Journal of medical economics 27 (1) (2024)
Rui Cai, Laetitia Gerlier, Martin Eichner, Markus Schwehm, Sankarasubramanian Rajaram, Joaquin Mould-Quevedo, Mark Lamotte
Cost-effectiveness of the cell-based quadrivalent versus the standard egg-based quadrivalent influenza vaccine in Germany. Journal of medical economics 24 (1) (2021)